BioSpace News Archive

Policy

Biopharma Update on the Novel Coronavirus: November 3

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 3, 2020.

November 3, 2020
·
5 min read
·
BioSpace Editorial Staff
Drug Development

Three Biotechs Shutter Clinical Programs After Futility Analysis or Failed Trials

Three biopharma companies recently shuttered their clinical programs after either their compounds failed clinical trials or interim futility analysis suggested they were unlikely to meet their clinical endpoints. Here’s a look.

November 3, 2020
·
3 min read
·
Mark Terry
Drug Development

Karyopharm Therapeutics Eyes New Indication in Solid Tumors for Xpovio

The company announced positive topline results in its Phase III study of Xpovio (selinexor) in patients with advanced unresectable dedifferentiated liposarcoma, which sets up potential approval in this indication.

November 3, 2020
·
2 min read
·
Alex Keown
Job Trends

Opportunity Horizon – A Look at Recent Life Sciences Job Expansions

The life sciences industry is one of the fastest growing in the world. BioSpace provides a rundown of companies announcing facility and job expansions across the U.S. and beyond.

November 3, 2020
·
4 min read
·
Kate Goodwin
Drug Development

Aptevo’s Phase I APVO436 Trial on Right Track Against AML

Aptevo is a clinical-stage biotech company developing novel therapeutics built on its proprietary platform ADAPTIR™technology which is modular and includes bispecific molecules that recognize and bind to two unique target antigens simultaneously.

November 3, 2020
·
2 min read
·
Heather McKenzie
Deals

Biopharma Money on the Move: October 28 – November 3

Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.

November 3, 2020
·
4 min read
·
Kate Goodwin
Drug Development

GW Pharma Hopes to Bring Its Second Cannabis-Based Drug Nabiximols to Market in the U.S.

GW Pharmaceuticals hopes to bring its cannabis-based treatment nabiximols for multiple sclerosis spasticity to the United States.

November 3, 2020
·
3 min read
·
Alex Keown
Pharm Country

Researchers Discover How Pancreatic Cancer Cells Evade Starvation

A new study suggests that pancreatic cancer cells avoid starvation by signaling to nerves. This encourages them to grow into dense tumors and release the nutrients the cells need to survive.

November 3, 2020
·
3 min read
·
Krystle Vermes
Drug Development

Study: Biogen’s Lupus Drug Candidate BIIB059 Reduces Disease Activity Better Than Placebo

Additional findings from Biogen’s Phase II LILAC study, announced today, show the company’s lupus drug candidate BIIB059 is superior to placebo for reducing joint disease activity in patients with systemic lupus erythematosus.

November 3, 2020
·
3 min read
·
Brandon May
Policy

Prevail and Alector Both Declare Victory in Year-Long Legal Battle

Both sides claim to be pleased with arbitration results in dispute over Prevail CEO’s alleged breach of contract from time with Allector.

November 3, 2020
·
3 min read
·
Kate Goodwin